证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-----------------------|----------------------------------|-----------------------------------------------------------------------| | | | | | 投资者关系 | □特定对象调研 □分析师会议 | | | 活动类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名 | 2022 年 5 月 19 日下午 | | | 称 | 广大投资者 | | | | | | | 会议时间及 会议方式 | 2022 年 5 月 19 日下午 | 通过上证路演中心视频录播、网络文字互动相结合的方式 | | 上市公司接 | 董事长兼总经理，胡克 | | | 待人员姓名 | 董事、董事会秘书兼财务总监，于浩 | | | ...

编号：2022-007 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------------|----------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | 现场参观 | | | | 其他 | （请文字说明其他活动内容）策略会 | | | | | | 会议时间、参与 | 2022 年 6 月 1 日下午 | 电话会议 | | 单位名称及会 | 华创证券，农银汇理基金 | | | 议方式 | 2022 年 6 月 2 日下午 | 电话会议 | | | 民生证券，广发基金 | | | | 2022 年 6 月 6 日下午 | 电话会议 | | | 民生证券，华商基金 | | | | 2022 年 6 月 6 日下午 | 电话会议 | | | 华创证券，万家基金 | | ...

编号：2022-006 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------|----------------------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 | （请文字说明其他活动内容）策略会 | | 会议时间、参与 | 2022 年 5 月 9 日下午 | 策略会 | | 单位名称及会 | | 华创证券，华创证券自营，进门财经，高信百诺，华商基金，新华基金， | | 议方式 | | 歌斐资产，金百镕投资，浦银安盛基金，中银国际证券，安信基金，熙 | | | 2022 年 5 月 13 日下午 东方证券， ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 15%[12]. - The company's operating revenue for the first half of 2022 was CNY 155,516,645.45, a decrease of 14.62% compared to the same period last year[18]. - The net profit attributable to shareholders was CNY 22,097,910.67, down 35.18% year-on-year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20,440,370.72, a decline of 38.40% compared to the previous year[18]. - The gross profit margin improved to 45%, up from 40% in the same period last year, reflecting better cost management[12]. - The company reported a total revenue of 6,900 million RMB, with a year-on-year increase of 1,173.76 million RMB, representing a growth of approximately 20.5%[50]. - The company's operating revenue for the reporting period was ¥155,516,645.45, a decrease of 14.62% compared to ¥182,153,328.85 in the same period last year[72]. - Net profit attributable to shareholders was 22.10 million yuan, down 35.18% year-on-year, with a non-recurring net profit of 20.44 million yuan, down 38.40%[56]. Research and Development - Research and development expenses increased by 25% to RMB 50 million, focusing on new technologies in analytical instruments[12]. - The R&D expenditure accounted for 10.98% of operating revenue, an increase of 3.24 percentage points year-on-year[19]. - The company achieved a total R&D investment of ¥17,079,801.28, representing a 21.08% increase compared to the previous year[41]. - R&D investment accounted for 10.98% of total revenue, up from 7.74% in the same period last year, indicating a 3.24 percentage point increase[41]. - The company has obtained a total of 96 authorized patents, including 2 new invention patents during the reporting period[38]. - The company has developed a fully automated experimental detection platform that integrates sample collection, processing, automated injection, analysis, and intelligent data analysis[25]. - The company is developing a fully automatic sample purification instrument for radioactive element extraction, which replaces manual operations to avoid radiation exposure[36]. Market Expansion and Strategy - The company expects a revenue growth forecast of 10% for the second half of 2022, driven by new product launches and market expansion strategies[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[12]. - The company is focusing on expanding its product offerings and enhancing the performance of its existing products to meet the growing demands of downstream application fields[34]. - The company is actively developing new sample pretreatment products and analysis testing instruments to enhance product performance and expand its market share in food testing and environmental monitoring[34]. - The company is focusing on expanding its market presence in the life sciences, food, and environmental sectors, with significant applications in disease control[45]. Shareholder and Governance Matters - The board has approved a share buyback program of up to RMB 20 million to enhance shareholder value[12]. - The company has committed to maintaining a dividend payout ratio of K%, ensuring consistent returns for investors[117]. - The company will strictly adhere to the relevant laws and regulations regarding shareholding lock-up commitments and will not engage in any share reduction behavior that violates these commitments during the lock-up period[118]. - The company has established a commitment to adhere to the rules regarding share transfer for directors and senior management[106]. - The company will ensure that any share reduction price will not be lower than the IPO price within 2 years post-lock-up[106]. Operational Challenges - The decline in revenue and profit was primarily attributed to the impact of COVID-19 on operations, particularly in East and North China[18]. - The company increased its inventory by CNY 24,123,000 due to longer procurement cycles and anticipated price increases for raw materials[18]. - The project for upgrading the intelligent analysis detection system production line faced delays due to local pandemic control measures, affecting construction progress[152]. - The project for the production of experimental analysis instrument consumables was impacted by global pandemic-related shipping and personnel restrictions, causing delays in equipment arrival and training[153]. Corporate Social Responsibility - The company has implemented environmental protection measures, including the recovery and treatment of industrial wastewater and solid waste, ensuring compliance with pollution discharge standards[98]. - In July 2022, the company donated to the Tianjin Red Cross to support rural revitalization efforts in Gansu Province[100]. - The company signed a partnership agreement in August 2022 to assist in economic development and improve working conditions in a village in Inner Mongolia[100].

Financial Performance - The company's operating revenue for 2021 was CNY 368.86 million, an increase of 5.81% compared to 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 69.41 million, reflecting a growth of 6.44% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 62.99 million, up by 7.99% from the previous year[20]. - The company's total assets at the end of 2021 were CNY 892.47 million, a 4.70% increase from 2020[21]. - The net assets attributable to shareholders increased by 6.27% to CNY 786.43 million at the end of 2021[21]. - Basic and diluted earnings per share for 2021 were CNY 1.04, down 11.11% compared to the previous year[22]. - The net cash flow from operating activities decreased by 41.25% to CNY 49.08 million, primarily due to increased inventory and supply chain disruptions[23]. - The company's operating costs for the reporting period were 190.19 million yuan, an increase of 6.17% compared to the same period last year, primarily due to rising commodity prices and adjustments in sales prices[118]. - The company's sales expenses amounted to 53.27 million yuan, up 13.93% year-on-year, driven by an increase in sales personnel and overall salary expenses rising by 16.63%[118]. Research and Development - The R&D expenditure as a percentage of operating revenue was 8.51%, slightly up from 8.42% in 2020[22]. - The company’s R&D investment reached 31.38 million yuan in 2021, a 6.95% increase compared to 2020, accounting for 8.51% of revenue[35]. - The company has established a postdoctoral research station to attract high-end talent and enhance its R&D capabilities[46]. - The company aims to enhance its technological capabilities and increase R&D investment to develop high-end instruments, leveraging national policies that support domestic instruments and import substitution[39]. - The company has developed several core technologies in analysis testing instruments, including fully automated solid-phase extraction and gel purification technologies, enhancing recovery rates and analysis accuracy[83]. Product Development and Innovation - The company launched a new product, the Inductively Coupled Plasma Mass Spectrometer (ICP-MS), in May 2021, achieving sales in semiconductor and medical fields[34]. - The company is developing two new projects related to ICP-MS, including the ICP-Q-TOF-MS, which is aimed at single-cell multi-element detection[36]. - The ICP-MS-MS project is focused on enhancing sensitivity and interference resistance for semiconductor applications[37]. - The company launched several new products during the reporting period, including the EV400H rotary evaporator and the HPSE-6 Ultra high-efficiency rapid solvent extractor, and received 21 new authorized patents and 2 software copyrights[38]. - The company has successfully integrated multiple sample pretreatment technologies into a single automated solution for clients[85]. Market Expansion and Sales Strategy - The company has established a broad sales network with subsidiaries in the US and Hong Kong, and has expanded into new industries such as nuclear and pharmaceutical sectors, while continuing to deepen its presence in traditional fields like environmental and food testing[40]. - The company is focusing on the development of new sample pretreatment products and analysis testing instruments to enhance its market position in food testing and environmental monitoring[71]. - The company plans to strengthen its sales team through specialized training to enhance professional knowledge and service capabilities[167]. - The company aims to achieve continuous revenue growth by increasing brand recognition and market share through diverse product offerings and efficient after-sales service[163]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements are accurate and complete[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has held 3 shareholder meetings, 5 board meetings, and 4 supervisory board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[173]. Financial Management and Shareholder Relations - The company plans to distribute a cash dividend of 3.50 RMB per 10 shares, totaling 23,450,000 RMB, which represents 33.78% of the net profit attributable to shareholders for 2021[5]. - The total number of shares held by the board members and senior management at the end of the reporting period is 32,063,370 shares, unchanged from the beginning of the year[180]. - The total pre-tax remuneration for the board members and senior management during the reporting period amounts to 9.65 million yuan[180]. - The company is focused on creating a harmonious development environment and improving investor relations through timely and accurate information disclosure[174]. Risk Management - The company has detailed the potential risks in its operations, which can be found in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks related to market expansion, including potential adverse changes in cooperation with major distributors[108]. - The company is exposed to foreign exchange risks due to a significant portion of export business settled in USD and EUR[110].

2022 年第一季度报告 证券代码：688056 证券简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2022 年第一季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | --- | --- | --- | | | | 同期增减变动幅 | | | | 度(%) | | 营业收入 | 77,480,452.51 | -2.60 | | 归属于上市公司股东的净利润 | 11,915,323.71 | -18.02 | | 归属于上市公司股东的扣除非 | 11,169,850.78 | -20.02 | | 经常性损益的净利润 | | | | 经营活动产生的现金流量净额 | -19,793,009.92 | 不适用 | 1 / 13 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 ...

2021 年第三季度报告 证券代码：688056 证券简称：莱伯泰科 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 86,637,366.07 | 0.32 | 268,790,694.92 | 19.39 | | 归属于上市公司股东的 净利润 | 19,230,814.23 | 15.14 | 53,322,446.36 | 47.02 | | 归属于上市公司股东的 | | | | | | 扣除非经常性损益的净 | 16,832,213.44 | 2.13 | 50,012,031.01 | 33.05 | | 利润 | | | | | 北京莱伯泰科仪器股 ...

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the first half of 2021, representing a year-on-year increase of 20%[13]. - The company's operating revenue for the first half of 2021 was ¥182,153,328.85, representing a 31.27% increase compared to the same period last year[20]. - The net profit attributable to shareholders was ¥34,091,632.13, a 74.23% increase year-over-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥33,179,817.57, up 57.20% from the previous year[20]. - The basic and diluted earnings per share were both ¥0.51, reflecting a 30.77% increase compared to the same period last year[21]. - The company reported a total revenue of 39.2 million RMB, with a net profit of approximately 10.66 million RMB, indicating a significant increase in profitability compared to the previous period[53]. - The company reported a total comprehensive income of CNY 21,888,389.42 for the first half of 2021, reflecting a significant increase compared to the previous period[180]. Research and Development - Research and development expenses increased by 30% to 150 million RMB, reflecting the company's commitment to innovation and product development[13]. - The total R&D expenditure for the period was ¥14,106,104.16, an increase of 13.19% compared to the previous period's ¥12,462,548.77[40]. - The research and development expenditure accounted for 7.74% of operating revenue, down 1.24 percentage points from the previous year[21]. - The company has established a research and development system focused on food testing, environmental monitoring, and agricultural product testing, among other key areas, contributing to its strong technical capabilities[27]. - The company has obtained 11 new authorized patents and 1 new software copyright during the reporting period, bringing the total to 76 authorized patents and 28 software copyrights[37]. Market Expansion and Product Development - The company plans to launch three new products in Q3 2021, focusing on advanced analytical instruments, which are expected to contribute an additional 200 million RMB in revenue[13]. - The company aims to expand its market reach into Southeast Asia, targeting a 10% market share within the next two years[13]. - The company is actively developing new sample pretreatment products and platforms to enhance product performance and expand its market share in food testing and environmental monitoring[34]. - The company is focusing on expanding its market presence in environmental testing, particularly in VOCs detection, driven by national policies such as "Air Ten Measures" and "Soil Ten Measures"[46]. - The company plans to continue high-level R&D investment to maintain a competitive edge in high-end instrument products[64]. Financial Health and Assets - The company's total assets decreased by 2.85% to ¥828,043,371.25 compared to the end of the previous year[20]. - The net assets attributable to shareholders increased by 1.90% to ¥754,151,246.52 at the end of the reporting period[20]. - The company's cash and cash equivalents were CNY 502,684,576.01, down from CNY 616,546,148.93, a decline of around 18.4%[149]. - The total owner's equity increased to CNY 755,182,373.54 from CNY 740,920,921.08, reflecting an increase of approximately 1.5%[151]. - The company reported a total of 5,500,000 shares held by Beijing Hongjing Haorun Management Consulting Co., Ltd., representing 8.21% of the total shares[140]. Strategic Initiatives and Future Outlook - Future outlook includes a projected revenue growth of 25% for the full year 2021, driven by market expansion and new product launches[13]. - The company is exploring potential acquisitions to enhance its technology portfolio and market presence, with a budget of 300 million RMB allocated for this purpose[13]. - The company aims to enhance the efficiency of radioactive strontium analysis from traditional methods taking one month to just a few hours[43]. - The company plans to build a manual production line for Empore Stagetips to optimize parameters and enhance product value, aiming for rapid commercialization[53]. - The company is committed to upgrading its product offerings and expanding its market presence in response to increasing demands for high-end laboratory instruments[33]. Risks and Challenges - The company has identified key risks, including market competition and regulatory changes, which are detailed in the risk factors section of the report[4]. - The company faces competition from international giants like Thermo Fisher and Agilent, which dominate the market, indicating a need for continued innovation and market expansion[33]. - The company experienced a significant recovery in performance due to improved pandemic control measures and proactive product launches[24]. Corporate Governance and Compliance - The board has approved a profit distribution plan, with no plans for capital increase through reserves for this period[5]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its IPO[99]. - The company will strictly adhere to relevant regulations regarding the lock-up period for shares and will not engage in any share reduction activities that violate these commitments[100]. - The company has a commitment to not seek preferential treatment in business cooperation due to its controlling position[111]. - The company will cooperate with regulatory bodies in case of any violations related to the prospectus[110].

2021 年第一季度报告 公司代码：688056 公司简称：莱伯泰科 北京莱伯泰科仪器股份有限公司 2021 年第一季度报告 1 / 22 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 10 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | | | | 减(%) | | | 总资产 | 856,543,844.97 | 852,373,343.14 | | 0.49 | | 归属于上市公司 | 755,274,907.78 | 740,055,405.51 | | 2.06 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | -1,042,761.18 | -3,079,936.91 | | ...

2020 年年度报告 北京莱伯泰科仪器股份有限公司 2020 年年度报告 1 / 221 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细描述了公司可能存在的风险，具体内容敬请查阅本报告"第四节 经营情 况讨论与分析"之"二、风险因素"部分。 三、 公司全体董事出席董事会会议。 公司代码：688056 公司简称：莱伯泰科 本报告中所涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 九、 是否存在被控股股东及其关联方非经营性占用资金情况 四、 信永中和会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 五、 公司负责人胡克、主管会计工作负责人于浩及会计机构负责人（会计主管人员）张瑜声明：保证 年度报告中财务报告的真实、准确、完整。 六、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年利润分配方案为：公司拟以实施2020年度权益分派股权登记日登记的总 ...